Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Other Non-Current Liabilities (2016 - 2025)

Dare Bioscience (DARE) has disclosed Other Non-Current Liabilities for 10 consecutive years, with $5.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities rose 16.28% year-over-year to $5.2 million, compared with a TTM value of $5.2 million through Sep 2025, up 16.28%, and an annual FY2024 reading of $4.7 million, up 21.26% over the prior year.
  • Other Non-Current Liabilities was $5.2 million for Q3 2025 at Dare Bioscience, up from $4.9 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $5.2 million in Q3 2025 and bottomed at $1.0 million in Q2 2021.
  • Average Other Non-Current Liabilities over 4 years is $4.2 million, with a median of $4.5 million recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities changed 0.0% in 2021, then grew 21.26% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $1.0 million in 2021, then skyrocketed by 291.37% to $3.9 million in 2023, then increased by 21.26% to $4.7 million in 2024, then increased by 10.0% to $5.2 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for DARE at $5.2 million in Q3 2025, $4.9 million in Q2 2025, and $4.7 million in Q1 2025.